Stay updated with breaking news from Evidence Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Upcoming Hearings - March 22 - Senate Committee on Health, Education, Labor and Pensions Hearing: “Taxpayers Paid Billions For It: So Why Would Moderna...
Equipped with the knowledge that the payer community has heavily restricted access to amyloid directed antibodies, Biogen and Eisai have elected to...
Lecanameb, the newly FDA approved drug, is likely to cost about $27,000 a year, according to various websites. While some with Mild Cognitive Impairment can afford the drug, most cannot. This inequity...
Crain's Health Pulse is your source for actionable, exclusive and inside news on the health care industry.
/PRNewswire/ -- The Alzheimer's Association filed a formal request asking the Centers for Medicare & Medicaid Services (CMS) to provide full and unrestricted...